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Abstract
Purpose It is suspected that delayed surgery after neoadjuvant chemotherapy (NACT) leads to a worse outcome in breast 
cancer patients. We therefore evaluated possible influencing factors of the time interval between the end of NACT and surgery.
Methods All patients receiving NACT due to newly diagnosed breast cancer from 2015 to 2017 at the Department of 
Gynecology, Saarland University Medical Center, were included. The time interval between end of NACT and surgery was 
defined as primary endpoint. Possible delaying factors were investigated: age, study participation, outpatient and inpatient 
presentations, implants/expander, MRI preoperatively, discontinuation of chemotherapy, and genetic mutations.
Results Data of 139 patients was analyzed. Median age was 53 years (22–78). The time interval between end of NACT and 
surgery was 28 days (9–57). Additional clinical presentations on outpatient basis added 2 days (p = 0.002) and on inpatient 
basis added 7 days to time to surgery (p < 0.001). Discontinuation of NACT due to chemotherapy side effects prolonged 
time to surgery by 8 days (p < 0.001), whereas discontinuation due to disease progress did not delay surgery (p = 0.6). In 
contrast, a proven genetic mutation shortened time to surgery by 7 days (p < 0.001). Patient’s age, participation in clinical 
studies, oncoplastic surgery, and preoperative MRI scans did not delay surgery.
Conclusion Breast care centers should emphasize a reduction of clinical presentations and a good control of chemotherapy 
side effects for breast cancer patients to avoid delays of surgery after NACT.
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Introduction
Breast cancer is the most frequent malign disease in women. 
Lifetime risk adds up to 1:8 [1] and the incidence of breast 
cancer has even increased over the last years so that in 2020 
about 77,600 new diseases may be expected in Germany. 
Breast cancer mortality has dropped since 1990 thanks to 
many new successful therapy strategies [1]. One of the 
therapy strategies is the neoadjuvant chemotherapy (NACT) 
which allows disease downstaging and higher rates of breast-
conserving therapy [2]. According to German guidelines, the 
operation following NACT should be performed 2–4 weeks 
after the end of NACT to bypass the leukocyte nadir [3]. 
There is compelling evidence that a delayed therapy onset 
of adjuvant chemotherapy worsen outcome [4, 5], which 
was also shown for neoadjuvant settings [6]. Sanford et al. 
reported worse outcome when time to surgery exceeds 
8 weeks after NACT [6]. Several factors might influence 
this time interval, and especially prolonging factors are of 
considerable interest to improve clinical pathways.
We therefore determined the time interval between the 
end of NACT and surgery, and investigated possible influ-
encing factors: age, study participation, outpatient and inpa-
tient presentations, implants/expander, MRI preoperatively, 
discontinuation of chemotherapy, and genetic mutations. 
We previously reported influences on the onset of NACT 
based on the same register [7]. Onset of NACT was delayed 
by additional clinical presentations, making it particularly 
interesting, whether this also applies to the time between 
NACT and surgery.
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Data were collected of all patients receiving a neoadjuvant 
chemotherapy (NACT) at the Department of Gynecology, 
Saarland University Medical School from 2015 to 2017. 
Therapy schedule was based on diagnosis and determina-
tion of prognostic factors. The primary endpoint was the 
time interval between the end of NACT (date of last infu-
sion) and date of surgery.
Patient’s age, stage, and tumor biology were recorded. 
The type of operation was documented (breast-preserving 
therapy versus mastectomy and reconstruction with breast 
implants or expander). Chemotherapy plans were based 
on clinical studies or standard therapy was applied. From 
2015 to 2017, the following neoadjuvant study designs 
were addressed: GAIN II, GeparOcto, GeparX, Nadens, 
and Adapt studies. The number of presentations in the 
hospital was recorded, either on outpatient or inpatient 
basis. It was noted whether there was a genetic mutation 
or whether additional imaging (for example MRI) had to 
be performed before surgery. Furthermore, discontinuation 
of chemotherapy and reasons for discontinuation (therapy 
complications/disease progress) were recorded.
Data management and statistics
Patient’s data were reviewed in the hospital’s digital docu-
mentation system (SAP, Walldorf, Germany). Data was 
collected using Microsoft Excel  2010® (Microsoft, Red-
mond, USA). Further statistics were performed with SPSS 
24.0 (IBM, Armonk, USA). Quantitative parameters like 
time intervals, patient’s age, and number of clinical pres-
entations are presented as median and range. Qualitative 
parameters like tumor biology, type of operation (breast-
conserving therapy, mastectomy or reconstruction with 
breast implants or expander), and other influencing factors 
are given as frequencies. Univariate regression analysis 
was performed, with bootstrapping of 100,000 samples, 
to determine the influence of the following factors on the 
time interval between the end of NACT and surgery: age, 
study participation, clinical presentations, reconstructive 
surgery (implants/expander), preoperative MRI, discon-
tinuation of chemotherapy (therapy complications/disease 
progress), and genetic mutation. All procedures performed 
in the study involving human participants were in accord-
ance with the ethical standards of the institutional and/or 
national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical 
standards. Informed consent was obtained from every indi-
vidual participant included in the study.
Results
A total of 152 patients were scheduled for NACT between 
2015 and 2017. After exclusion of 13 patients with insuf-
ficient records, 139 patients proved to be evaluable. Overall 
median time between the end of NACT and surgery was 
28 days (9–57). The patient’s median age was 54 years 
(22–78).
Table 1 illustrates tumor and therapy characteristics. 
About half of the patients had a complete remission (ypT0) 
after NACT. None of the patients had primary metastasis. 
The most common surgical procedure was breast-conserv-
ing therapy (65%). The luminal A subtype was rare (4%), 
whereas luminal B, Her2-positive and triple-negative 
subtypes were equally distributed (32, 34, 30%). Genetic 
mutation was rare (4%). 90 patients (65%) were treated 
with standard chemotherapies according to guidelines and 
49 (35%) received study therapies. The major part (47%) 
was treated according to the GAIN II protocol (23 patients) 
[8] followed by GeparOcto (18 patients) [9]. A total of 27 
patients (19%) discontinued chemotherapy. Most of the 
patients discontinued chemotherapy due to side effects (20 
patients) and some due to disease progress (4 patients). Ther-
apy complications were polyneuropathy in nine patients, 
changes of laboratory values (for example increased liver 
value) in four patients, skin lesions (for example erythema) 
in three patients, port infection in one patient, and discon-
tinuation of chemotherapy due to general deterioration in 
three patients.
Between the end of chemotherapy and operation, the 
patients had a median of 1 (0–7) outpatient presentations 
and a median of 0 (0–2) inpatient presentations. The major 
reasons for clinical presentations were planning of surgery 
(98%) followed by side effects of chemotherapy (17%), 
which is consistent with main reasons for repetitive appoint-
ments due to planning of surgery (29%) and due to side 
effects of chemotherapy (11%). In rare cases, a preoperative 
MRI (14%) or echocardiography (9%) was performed before 
operation (Table 2).
Clinical presentations on outpatient and inpatient basis 
considerably prolonged time to surgery. Every outpatient 
presentation added 2 days and every inpatient presenta-
tion added 7 days to the time to surgery. Discontinuation 
of NACT due to side effects also prolonged time to sur-
gery by an average of 8 days, whereas discontinuation due 
to disease progress had no significant influence. A proven 
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genetic mutation shortened the time to surgery by an aver-
age of 7 days. Age, study participation, oncoplastic surgery 
(implants / expander), and preoperative MRI did not delay 
surgery (Table 3).






























 Breast-conserving therapy 90 64.7
 Subcutaneous mastectomy 14 10.1
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Reasons
 Side effects of chemotherapy 20 14.3
 Disease progress 4 2.9

























 Imaging (MRI, CT) 19 13.6
Main reason for repetitive appointments
 All 56 40
 Planning of surgery 40 28.6
 Side effects of chemotherapy 16 11.4







Age 0.007 −0.1 to 0.1 0.054
Study participation 0.5 −2.4 to 3.5 0.72
Outpatient presenta-
tions
2.2 0.8 to 3.6 0.002
Inpatient presenta-
tions
6.9 3.9 to 10.3  < 0.001
Implants/expander 3 −1.4 to 7.6 0.189








−1 −5.7 to 2.7 0.622
Genetic mutation −6.6 −8.8 to −4.5  < 0.001
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Discussion
Median time between NACT and surgery was 28 days in 
accordance with current German guidelines which recom-
mend surgery 2–4 weeks after NACT [3]. Similar results 
were reported in a retrospective analyses of 1101 patients 
with 33 days between NACT and surgery [6]. Additionally, 
outcome seems to worsen when surgery is performed more 
than 8 weeks after NACT [6].
Worse outcomes by a delayed therapy onset was also 
shown for adjuvant settings. Especially patients with stage 
III of breast cancer, trastuzumab-treated Her2-positive 
tumors and triple negative carcinomas had inferior out-
comes when time to chemotherapy was longer than 60 days 
compared to a therapy onset below 30 days after surgery 
[4]. Consistently, recurrence-free survival and overall 
survival decreases in patients with triple-negative breast 
cancer when chemotherapy started more than 30 days 
after surgery [5]. However, these studies investigated 
adjuvant chemotherapy settings, where chemotherapy is 
performed after surgery. There is still missing data for 
limits of the time between NACT and surgery. However, 
therapy centers should stick to the recommended range 
of 2–4 weeks [3], as worse outcome can be expected if 
surgery is delayed [6].
To provide possible approaches to improve patient care, 
we analyzed possible influences on time to surgery after 
NACT. Additional clinical presentations prolonged time to 
surgery—outpatient presentations by 2 days and inpatient 
presentations by 7 days. The most common reason for a 
clinical presentation was planning of surgery. Most of the 
patients were seen after completion of chemotherapy to 
plan surgery, but some (2%) were seen earlier when regu-
lar presentations for sonographic controls were already 
scheduled close to the end of chemotherapy—this is not 
standard of care but saves time and resources. This might 
be a considerable approach to minimize clinical presenta-
tions. Especially patients with complicated cases could 
already be advised during clinical follow-ups of chemo-
therapy. The second most common reason for a clinical 
presentation were side effects of chemotherapy. A good 
control of chemotherapy side effect is thus recommend-
able. For example, by routine antiemetic prophylaxis or 
GCSF (granulocyte colony stimulating factor) prepara-
tions. Taken together, breast care centers should optimize 
clinical pathways and the prevention of chemotherapy side 
effects to minimize clinical presentations and accelerate 
time to surgery.
Patient’s age had no influence on time to therapy onset, 
nor did study participation (Table 3). A possible reason 
might be that patients participating in clinical studies had 
the most part of administrative and structural restraints 
(like checking of inclusion/exclusion criteria, control of 
morphologic and biologic assessment, etc.) already done 
before NACT. One might expect that this delays the onset 
of NACT, but our previous analysis based on the same reg-
ister showed no delay of NACT by study participation [7].
Oncoplastic surgery did not prolong time to surgery. 
Oncoplastic surgery offers a further approach for extending 
breast conserving surgery possibilities, with wide excisions 
and aesthetic results [10]. Although oncoplastic surgery is 
performed more frequently in patients with larger or multi-
focal tumors, there is no increased rate of local recurrences 
or re-operations [11]. Taken together, there is no reason to 
forgo oncoplastic surgery in terms of outcome and time to 
surgery.
Preoperative imaging (MRI scan) seemed to delay time 
to surgery on average by 4 days without reaching statistical 
significance (Table 3). This might be due to the limited num-
ber of patients. Previous studies reported delays of 11 [12] 
or even 22 days [13]. However, both studies were done in 
adjuvant therapy settings. The need for a preoperative MRI 
might be already clear during NACT, presumably allowing 
timely arrangements. Nevertheless, available data suggests 
that structural and organizational conditions should be opti-
mized to minimize a possible delay of surgery by preopera-
tive MRI.
The discontinuation of chemotherapy due to chemo-
therapy side effects prolonged time to surgery by 8 days. 
The majority of the patients stopped chemotherapy because 
of intolerable side effects, whereas a minority had disease 
progress. Patients suffering from side effects may have had 
to recover prior to surgery, presumably delaying time to sur-
gery. In contrast, discontinuation of chemotherapy due to 
disease progress did not delay time to surgery. This seems to 
be preferable, as patients with disease progress need timely 
surgical treatment.
Time to surgery was shortened by 7 days, if genetic 
mutation was confirmed. Since patients with proven BRCA 
mutation are more likely to develop breast cancer, primary 
mastectomy is usually advised [14]. Neoadjuvant settings 
give enough time for genetic counseling and testing, so that 
the result will already be available before completion of 
chemotherapy. Thus, the recommended surgical procedure 
is already clear before NACT is completed, making it appar-
ent that time to surgery is shortened.
Our study has some limitations. This study was performed 
in a single certified tertiary breast care center. Clinical path-
ways might differ in other centers. Sentinel-node-biopsy 
before NACT was standard of care in Germany during the 
study period. 72 patients (52%) in this study received SNB 
prior to NACT. With positive pretherapeutic lymph nodes 
(sonographic or according to SNB), an axillary lymphad-
enectomy was added to the surgical treatment after com-
pletion of chemotherapy. Nowadays, sentinel-node-biopsy 
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is performed after NACT, which may additionally prolong 
time to surgery. Furthermore, sample size is small, and thus 
regression analysis had to be performed with bootstrapping. 
At least, not all possible delaying factors were addressed 
in this study. For example, some patients might ask for a 
second opinion before surgery.
Conclusion
Median time between NACT and surgery is 28 days. To 
avoid delays of surgery, breast care centers should empha-
size a reduction of appointments for clinical presentations of 
patients with breast cancer after NACT. A good control of 
chemotherapy side effects is recommendable, as this is the 
major reason for chemotherapy discontinuation which delays 
surgery. Earlier clarity about the surgical procedure seems to 
shorten the time to surgery for patients with proven genetic 
mutation, thus early planning of surgery should be empha-
sized. At least, patient’s age, participation in clinical studies, 
oncoplastic surgery, discontinuation of chemotherapy due 
to disease progress, and preoperative MRI scans seems not 
to delay surgery.
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